PAI
AGIO icon

Palo Alto Investors’s Agios Pharmaceuticals AGIO Stock Holding History

Palo Alto Investors’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.23M Buy
213,601
+1,102
+0.5% +$31.2K 1.11% 23
2025
Q4 		$5.78M Sell
212,499
-52,998
-20% -$1.86M 0.81% 27
2025
Q3 		$10.7M Sell
265,497
-3,286
-1% -$124K 1.97% 17
2025
Q2 		$8.94M Sell
268,783
-7,795
-3% -$236K 1.9% 12
2025
Q1 		$8.1M Buy
+276,578
New +$9.17M 1.54% 16

Other funds holding AGIO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Palo Alto Investors's AGIO Position: Q1 2026 in Review

Palo Alto Investors increased its Agios Pharmaceuticals (AGIO) stake by 0.52% in Q1 2026, buying an estimated $31.2K and bringing the position to 213,601 shares worth $7.23M. The position accounts for 1.11% of the portfolio, ranked #23.

Palo Alto Investors first reported a position in AGIO in Q1 2025 and has held it in 5 quarters since. The position peaked at $10.7M in Q3 2025. 233 funds tracked by Wall St. Rank hold AGIO as of Q1 2026.

  • Palo Alto Investors held 213,601 shares of Agios Pharmaceuticals worth $7.23M as of Q1 2026.
  • Palo Alto Investors bought 1,102 Agios Pharmaceuticals shares in Q1 2026, an estimated $31.2K.
  • Agios Pharmaceuticals made up 1.11% of Palo Alto Investors's portfolio in Q1 2026, its #23 holding.
  • Palo Alto Investors first reported a position in Agios Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Palo Alto Investors's Agios Pharmaceuticals position peaked at $10.7M in Q3 2025.
  • 233 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2026.

Based on Palo Alto Investors's 13F filing for Q1 2026, filed 15 May 2026.